China’s experimental Covid-19 vaccine costs $60

Published October 18, 2020
A Chinese city is offering Sinovac Biotech’s experimental Covid-19 vaccine to essential workers and other high-risk groups as part of a national programme for about $60. —Reuters/File
A Chinese city is offering Sinovac Biotech’s experimental Covid-19 vaccine to essential workers and other high-risk groups as part of a national programme for about $60. —Reuters/File

BEIJING: A Chinese city is offering Sinovac Biotech’s experimental Covid-19 vaccine to essential workers and other high-risk groups as part of a national programme for about $60.

The eastern city of Jiaxing’s center for disease control and prevention (CDC) said in a statement on WeChat that two doses of the vaccine candidate, called CoronaVac, will cost 200 yuan ($29.75) per dose and that vaccinations for key groups including medical professionals have begun.

Chinese authorities have to date not released pricing details for potential Covid-19 vaccines. Hundreds of thousands of people have been given experimental vaccines in late-stage trials as part of an emergency inoculation programme launched in July.

It was not clear if Jiaxing city’s pricing includes subsidies. The city’s CDC declined to comment.

Sinovac did not immediately respond to a request for comment. Its vaccine is in late stage trials in Brazil, Indonesia and Turkey, and the company has said that an interim analysis of Phase three trial data could come as early as November.

Bio Farma, a state-owned firm in Indonesia which has reached a deal for at least 40 million doses from Sinovac, said this week the vaccine will cost around 200,000 rupiah ($13.60) per dose when it becomes available in the southeast Asian country.

China has said that while reasonable profits for companies are permitted, Covid-19 vaccines should be priced close to cost.

China National Pharmaceutical Group (Sinopharm) said in August that a vaccine candidate developed by a unit may cost no more than 1,000 yuan ($148.80) for two shots. An official at China’s National Health Commission has said, however, the price will be lower.

Published in Dawn, October 18th, 2020

Opinion

Who bears the cost?

Who bears the cost?

This small window of low inflation should compel a rethink of how the authorities and employers understand the average household’s

Editorial

Internet restrictions
Updated 23 Dec, 2024

Internet restrictions

Notion that Pakistan enjoys unprecedented freedom of expression difficult to reconcile with the reality of restrictions.
Bangladesh reset
23 Dec, 2024

Bangladesh reset

THE vibes were positive during Prime Minister Shehbaz Sharif’s recent meeting with Bangladesh interim leader Dr...
Leaving home
23 Dec, 2024

Leaving home

FROM asylum seekers to economic migrants, the continuing exodus from Pakistan shows mass disillusionment with the...
Military convictions
Updated 22 Dec, 2024

Military convictions

Pakistan’s democracy, still finding its feet, cannot afford such compromises on core democratic values.
Need for talks
22 Dec, 2024

Need for talks

FOR a long time now, the country has been in the grip of relentless political uncertainty, featuring the...
Vulnerable vaccinators
22 Dec, 2024

Vulnerable vaccinators

THE campaign to eradicate polio from Pakistan cannot succeed unless the safety of vaccinators and security personnel...